EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application digoxin tablets USP, 0.0625 mg, 0.125 mg and 0.25 mg. Aurobindo Pharma’s digoxin tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Lanoxin Tablets USP, of Concordia Pharmaceuticals.

Digoxin tablets are indicated for the treatment of mild to moderate heart failure in adults, increases myocardial contractility in pediatric patients with heart failure, and the control of ventricular response rate in adult patients with chronic atrial fibrillation.

Digoxin tablets has an estimated market size of US $2.1 million for the twelve months ending December 2021, as per IQVIA.